City

Clinical trials near Orlando, United States

Active studies with a listed research site in Orlando, United States.

27active studies

10recruiting now

13countries represented

56largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 3

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Alcohol Use DisorderCondition

Semaglutide, PlaceboTreatment

United States19 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-08-12 · NCT07218354See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowNot applicable

Feasibility and Acceptability of a Pediatric Referral to Summer Day Camps to Treat Obesity in Children From Low-Income Households

Obesity & OverweightCondition

Summer Day CampTreatment

United States1 locations

University of Central FloridaSponsor

Updated 2026-05-01 · NCT07464015See eligibility →

Recruiting nowNot applicable

Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise

ObesityCondition

Muscle Biopsy, Adipose BiopsyTreatment

United States2 locations

AdventHealth Translational Research InstituteSponsor

Updated 2026-03-27 · NCT06602141See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Type II Diabetes MellitusCondition

GL0034 Dose Level 1, GL0034 Dose Level 2Treatment

India, United States21 locations

Sun Pharmaceutical Industries LimitedSponsor

Updated 2026-03-18 · NCT07282743See eligibility →

Recruiting nowPhase 1

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

ObesityCondition

CagriSema (Cagrilintide B + semaglutide I), Low Energy DietTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2025-10-08 · NCT07184086See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, PlaceboTreatment

United States35 locations

KaileraSponsor

Updated 2026-07-15 · NCT07458269See eligibility →

Active, not recruitingPhase 1

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

ObesityCondition

Survodutide, SemaglutideTreatment

United States2 locations

Boehringer IngelheimSponsor

Updated 2026-05-12 · NCT06745284See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

United Kingdom, United States31 locations

Eli Lilly and CompanySponsor

Updated 2026-04-17 · NCT07232719See eligibility →

Active, not recruitingNot applicable

Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)

Obesity, Disorder of Lipid Storage and MetabolismCondition

ExerciseTreatment

United States1 locations

AdventHealth Translational Research InstituteSponsor

Updated 2026-03-30 · NCT01911091See eligibility →

Active, not recruitingPhase 1

To Determine Tolerability to Glucagon Infusion in Obese Subjects

ObesityCondition

GlucagonTreatment

United States1 locations

AdventHealth Translational Research InstituteSponsor

Updated 2026-03-30 · NCT02817659See eligibility →

Active, not recruitingPhase 1

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

ObesityCondition

Glucagon, GlucagonTreatment

United States1 locations

AdventHealth Translational Research InstituteSponsor

Updated 2026-03-30 · NCT03139305See eligibility →

Active, not recruitingNot applicable

Epigenetic Regulation of Human Adipose Tissue Distribution

ObesityCondition

Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS), Adipose tissue biopsiesTreatment

United States1 locations

AdventHealth Translational Research InstituteSponsor

Updated 2026-03-27 · NCT02728635See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

Active, not recruitingNot applicable

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

Obesity, Weight Change TrajectoryCondition

Revita Duodenal Mucosal Resurfacing (DMR), ShamTreatment

United States32 locations

Fractyl Health Inc.Sponsor

Updated 2026-03-03 · NCT06484114See eligibility →

Active, not recruitingNot applicable

Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)

Polycystic Ovary Syndrome, Metabolic DiseasesCondition

Intervention not listedTreatment

United States1 locations

AdventHealth Translational Research InstituteSponsor

Updated 2025-08-03 · NCT01745471See eligibility →

Active, not recruitingNot applicable

Clinical Investigation of the da Vinci Surgical System

Thymoma, Mediastinal TumorCondition

Robotic-assisted SurgeryTreatment

United States4 locations

Intuitive SurgicalSponsor

Updated 2024-06-03 · NCT05682742See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Orlando, United States

Current studies

Related cities